)
Visual
test
Astellas Pharma
Astellas Pharma (4503) investor relations material
Astellas Pharma Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary4 Feb, 2026
Executive summary
Achieved double-digit revenue growth (+10.2% YoY) and significant core operating profit increase (+48.6% YoY), driven by strong performance of strategic brands and cost optimization initiatives.
Upward revision of full-year forecasts for revenue, core operating profit, and full operating profit, reflecting robust business performance and continued momentum.
Strategic brands, including PADCEV, IZERVAY, VYLOY, VEOZAH, and XOSPATA, delivered substantial year-over-year sales growth, with PADCEV and VYLOY as key drivers.
Pipeline advanced with major regulatory approvals and positive clinical trial results, particularly for PADCEV, VYLOY, ASP3082, and ASP2138.
Gross profit increased 9.0% year-over-year to ¥1,286.6 billion.
Financial highlights
Revenue for Q3 YTD FY2025 reached ¥1,601.3 billion, up 10.2% year-over-year; core operating profit rose to ¥442.1 billion, up 48.6% year-over-year, with margin up to 27.6% (+7.1ppt YoY).
SG&A expenses decreased 1.0% year-over-year to ¥625.6 billion; R&D expenses fell 12.9% year-over-year to ¥218.9 billion, improving R&D ratio to 13.7%.
Free cash flow surged to ¥310.8 billion (Q3 YTD), up from ¥7.0 billion YoY; cash and equivalents increased to ¥254.3 billion.
Basic core earnings per share rose 48.6% year-over-year to ¥185.20.
On a full basis, profit for the period was ¥247.96 billion, reversing a loss of ¥24.15 billion in the prior year.
Outlook and guidance
Full-year FY2025 revenue forecast raised to ¥2,100 billion, up 3.4% from FY2024; core operating profit forecast increased to ¥520 billion (+6.1% YoY), and core profit to ¥385 billion (+5.5%).
Core OP margin expected to rise by 4.2 percentage points year-over-year to 24.8%.
R&D expenses projected at ¥315 billion, with increased late-stage development investments expected from Q4 and FY2026 onward.
No impairment indication as of Feb 2026.
Full basis profit forecast for FY2025 is ¥250 billion, up 38.9% year-over-year.
Explain the full basis operating profit turnaround.
What drove VYLOY's exceptional sales growth?
Detail the shift in the company's debt structure.
SMT's role in post-XTANDI LOE profitability
ASP3082 competitive edge and differentiation
XTANDI LOE mitigation strategy and tablet patent
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebHTOO
Resale registration for 71,429 shares via warrant, with proceeds only on exercise; financial risks persist. - 6 FebVSAT
Q3 revenue up 3% to $1.16B, net income $25M, strong cash flow, Ligado boost, satellite focus. - 6 FebWEC
Targets 7–8% EPS growth, $37.5B capex, and coal exit by 2032 amid surging data center demand. - 6 FebBR
Q2 FY26 recurring revenue grew 8% and adjusted EPS guidance was raised to 9-12%. - 6 FebFFWM
Merger vote includes new non-voting stock class with limited conversion and no voting rights. - 6 FebKKR
Charter amendments seek to modernize governance and establish one share, one vote by 2026. - 6 FebARI
Proposed $9B real estate loan portfolio acquisition highlights disciplined, long-term strategy. - 6 FebSMCI
Q2 revenue jumped 123% to $12.7B, with FY26 guidance raised to at least $40B. - 6 FebRJF
Record revenues and assets, higher dividend, and acquisitions despite lower net income. - 6 FebFFIE
Raising capital for global EV and AI expansion, with regulatory and dilution risks highlighted.
Next Astellas Pharma earnings date
Q4 202624 Apr, 2026
Astellas Pharma
Next Astellas Pharma earnings date
Q4 202624 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Astellas Pharma Inc., is a Japanese multinational pharmaceutical company that emerged from the merger between Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. in 2005. Astellas focuses on several key therapeutic areas including oncology, urology, immunology, cardiology, and infectious diseases, with a priority on research and development in infectious diseases, diabetes, gastrointestinal diseases, oncology, and central nervous system diseases. Astellas Pharma Inc. is headquartered in Tokyo, Japan, and its shares are listed on the Tokyo Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage